輸送培地の市場規模・シェア分析 (製品種類別・用途別・適応症別・エンドユーザー別)：世界の産業需要の予測 (2030年まで)

世界の輸送培地の市場規模は、2023年には31億130万米ドルに達し、2030年には4.6%のCAGRで成長し、42億1,060万米ドルに拡大すると推定されます。

この業界の成長の背景には、ウイルス性疾患に関する研究開発の増加、前臨床試験や診断試験のニーズの高まり、インフルエンザやヘルペスなどの感染性疾患の急増があります。

例えば、2022年には世界で約40万人がインフルエンザで死亡しています。同様に、約40億人がヘルペスに罹患しています。さらに、検査キットの受け入れを強化するための政府の取り組みが増加していることも、この業界を後押ししています。

製品種類別では、ウイルス輸送培地のカテゴリーが2023年には35%のシェアを占め、業界をリードしています。これは、COVID-19やサル痘のような感染症の予期せぬ発生が、感染者の検査と診断の必要性を高めているためと考えられます。

さらに、COVID-19の大流行時に治療と診断に対する意識が高まったことで、他のさまざまな感染症を検出するための関連製品に対する要求が高まっています。

適応症別では、ウイルス性疾患のカテゴリーが輸送培地市場を独占しています。さらに、このカテゴリーはこの10年間で最も速い速度で進歩します。これは主に、インフルエンザ、サル痘、ヘルペス、COVID-19、呼吸器合胞体ウイルス、水痘帯状疱疹などのウイルス性疾患の発生率が急上昇しているためと考えられます。

さらに、これらの病気の中でもインフルエンザとCOVID-19ウイルスは最も感染力の強い呼吸器系の病気であるため、世界的に深刻な懸念材料となっています。

エンドユーザー別では、診断検査室のカテゴリーが業界で最大シェアを占めています。これは、COVID-19の診断だけでなく検査に対するニーズが増加しているためです。これが診断検査室の設立を後押しし、仕事量を増加させています。

北米は業界を支配しています。これは、診断テストの急増、感染症に関する研究開発の増加、確立された医療制度、多数の製薬・バイオテクノロジー企業の存在によるものです。

基本的に、感染症、特にウイルス性疾患の急増は、各企業の収益創出を助ける主な要因です。

アジア太平洋はこの10年間、ライム病・結核・COVID-19のような感染症の有病率が上昇しているため、最も速いCAGRで成長すると思われます。

さらに、アジア太平洋 (特にインドと中国) では感染症患者の数が非常に多いです。そのため、診断の膨大なアンメットニーズを満たそうと、複数の企業が参入してきました。

ウイルス性疾患の研究開発の増加と感染症の発生率の高まりにより、輸送培地産業は今後数年間も進歩し続けると思われます。

目次

第1章 分析範囲

第2章 分析手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：製品種類別 (2017年～2030年)
• 市場収益：用途別 (2017年～2030年)
• 市場収益：適応症別 (2017年～2030年)
• 市場収益：エンドユーザー別 (2017年～2030年)
• 市場収益：地域別 (2017年～2030年)

第7章 北米市場

• 概要
• 市場収益：製品種類別 (2017年～2030年)
• 市場収益：用途別 (2017年～2030年)
• 市場収益：適応症別 (2017年～2030年)
• 市場収益：エンドユーザー別 (2017年～2030年)
• 市場収益：国別 (2017年～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 中南米市場

第11章 中東・アフリカ市場

第12章 米国市場

• 概要
• 市場収益：製品種類別 (2017年～2030年)
• 市場収益：用途別 (2017年～2030年)
• 市場収益：適応症別 (2017年～2030年)
• 市場収益：エンドユーザー別 (2017年～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供内容の一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Thermo Fisher Scientific Inc.
• Puritan Medical Products LLC
• Becton, Dickinson and Company
• COPAN Diagnostics Inc.
• Laboratory Corporation of America Holdings
• HiMedia Laboratories Pvt. Ltd.
• Trinity Biotech plc
• EKF Diagnostics Holdings plc
• Alpha Teknova Inc.
• Vircell S.L.
• Medical Wire & Equipment
• Lucence Health Inc.
• Merck KGaA
• Wuxi AppTec Co. Ltd.
• Bio-Rad Laboratories Inc.

第31章 付録

The transport media market is estimated to reach USD 3,101.3 million in 2023, which will increase to USD 4,210.6 million, with a 4.6% compound annual growth rate, by 2030.

The growth of this industry is because of the rising R&D on viral illnesses, increasing need for pre-clinical and diagnostic testing, and the surging occurrence of infectious ailments like influenza and herpes.

For example, in 2022, around 400,000 individuals died from influenza globally. Likewise, approximately 4 billion individuals have herpes. Moreover, the growing count of government initiatives to enhance the acceptance of testing kits is also boosting the industry.

The viral transport media category, based on product type, is leading the industry, with a 35% share, in 2023. This can be because of the unexpected outbreak of infectious ailments like COVID-19 and monkeypox, which boost the requirement for testing and diagnosis among the infected people.

Furthermore, the growing consciousness of treatment and diagnosis during the pandemic of COVID-19 has increased the requirement for related products for detecting various other infections.

The viral diseases category, on the basis of indication, is dominating the transport media market. Furthermore, the category will also advance at the fastest rate during this decade. This can be primarily because of the surging incidence of viral ailments like influenza, monkeypox, herpes, COVID-19, respiratory syncytial virus, and Varicella zoster.

Moreover, among these ailments, the influenza and COVID-19 virus are the most contagious respiratory ailments, therefore, they are a serious cause for worry globally.

The diagnostic laboratories category, based on end user, is the largest contributor to the industry. This is because of the increase in the need for testing as well as diagnosis of COVID-19. This has powered the formation of diagnostic labs and increased their workload.

North America is dominating the industry. This is because of the surging number of diagnostic tests, rising R&D on infectious ailments, well-established healthcare system, and the existence of numerous pharma and biotech businesses.

Basically, the surging occurrence of infectious illnesses, particularly viral ailments, is a main factor that assists in revenue generation for industry players.

APAC will advance at the fastest compound annual growth rate during this decade, because of the rising prevalence of infectious illnesses like Lyme disease, tuberculosis, and COVID-19.

Moreover, the number of people with infectious illnesses is quite high in APAC, particularly in India and China. Therefore, several industry players have arrived to satisfy the vast unmet necessity for diagnosis.

It is because of the increasing research & development in viral ailments and the mounting incidence of infectious illnesses, the transport media industry will continue to progress in the coming years.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product type
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by indication
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product Type (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
• 6.4. Market Revenue, by Indication (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product Type (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
• 7.4. Market Revenue, by Indication (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product Type (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by Indication (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product Type (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by Indication (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product Type (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by Indication (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product Type (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by Indication (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product Type (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)
• 12.4. Market Revenue, by Indication (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product Type (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)
• 13.4. Market Revenue, by Indication (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product Type (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)
• 14.4. Market Revenue, by Indication (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product Type (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)
• 15.4. Market Revenue, by Indication (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product Type (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)
• 16.4. Market Revenue, by Indication (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product Type (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)
• 17.4. Market Revenue, by Indication (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product Type (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)
• 18.4. Market Revenue, by Indication (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product Type (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)
• 19.4. Market Revenue, by Indication (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product Type (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)
• 20.4. Market Revenue, by Indication (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product Type (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)
• 21.4. Market Revenue, by Indication (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product Type (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)
• 22.4. Market Revenue, by Indication (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product Type (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)
• 23.4. Market Revenue, by Indication (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product Type (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)
• 24.4. Market Revenue, by Indication (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product Type (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)
• 25.4. Market Revenue, by Indication (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product Type (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)
• 26.4. Market Revenue, by Indication (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product Type (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)
• 27.4. Market Revenue, by Indication (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product Type (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)
• 28.4. Market Revenue, by Indication (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Thermo Fisher Scientific Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Puritan Medical Products LLC
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
• 30.3. Becton, Dickinson and Company
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. COPAN Diagnostics Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
• 30.5. Laboratory Corporation of America Holdings
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. HiMedia Laboratories Pvt. Ltd.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
• 30.7. Trinity Biotech plc
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. EKF Diagnostics Holdings plc
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Alpha Teknova Inc.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Vircell S.L.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
• 30.11. Medical Wire & Equipment
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
• 30.12. Lucence Health Inc.
  • 30.12.1. Business overview
  • 30.12.2. Product and service offerings
• 30.13. Merck KGaA
  • 30.13.1. Business overview
  • 30.13.2. Product and service offerings
  • 30.13.3. Key financial summary
• 30.14. Wuxi AppTec Co. Ltd.
  • 30.14.1. Business overview
  • 30.14.2. Product and service offerings
  • 30.14.3. Key financial summary
• 30.15. Bio-Rad Laboratories Inc.
  • 30.15.1. Business overview
  • 30.15.2. Product and service offerings
  • 30.15.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports